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DNA methylation in mammals occurs on cyto-
sine residues at the C5 position of the pyrimidine 
ring primarily at the palindromic dinucleotide 
sequence 5-CG-3 (Bestor, 1990; Lister et al., 
2009). This covalent modification is essential for 
normal mammalian development (Li et al., 1992; 
Okano et al., 1999) and has been linked to tran-
scriptional repression and formation of repressive 
chromatin structures on the underlying DNA 
(Jaenisch and Bird, 2003). DNA methylation is 
associated with imprinted regions, the inactive X 
chromosome, and parasitic DNA elements and 
their relics (Bestor, 2000; Lister et al., 2009). The 
role of DNA methylation in regulation of gene 
expression remains controversial (Bird, 1995; 
Bestor, 1998) but is generally thought to be asso-
ciated with gene silencing.
CpG islands are genomic regions defined 
by a regional frequency of CG dinucleotides that 
approaches statistical expectations (Gardiner-
Garden and Frommer, 1987). Presumably, this 
CG dinucleotide content is retained because these 
regions remain unmethylated in the germ line   
(Jones et al., 1992) or are subject to genetic selec-
tion (Rollins et al., 2006). These sequences are 
found in association with promoters in the human   
genome at high frequency (Saxonov et al., 
2006). Their aberrant methylation in pathological 
processes is associated with loss of expression   
of the genes with which they are tightly linked 
(Feinberg et al., 2002). In mammalian cells, it is 
widely accepted that DNA methylation at pro-
moter  regions  inhibits  transcription  initiation 
(Bird and Wolffe, 1999). In contrast, a body of 
evidence also indicates that the process of tran-
scription elongation is largely refractory to DNA 
methylation in mammals (Robertson and Wolffe, 
2000). A recent analysis of the methylation status   
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Aberrant DNA methylation commonly occurs in cancer cells where it has been implicated in 
the epigenetic silencing of tumor suppressor genes. Additional roles for DNA methylation, 
such as transcriptional activation, have been predicted but have yet to be clearly demon-
strated. The BCL6 oncogene is implicated in the pathogenesis of germinal center–derived  
B cell lymphomas. We demonstrate that the intragenic CpG islands within the first intron 
of the human BCL6 locus were hypermethylated in lymphoma cells that expressed high 
amounts of BCL6 messenger RNA (mRNA). Inhibition of DNA methyltransferases decreased 
BCL6 mRNA abundance, suggesting a role for these methylated CpGs in positively regulat-
ing BCL6 transcription. The enhancer-blocking transcription factor CTCF bound to this 
intronic region in a methylation-sensitive manner. Depletion of CTCF by short hairpin RNA 
in neoplastic plasma cells that do not express BCL6 resulted in up-regulation of BCL6 
transcription. These data indicate that BCL6 expression is maintained during lymphoma-
genesis in part through DNA methylation that prevents CTCF-mediated silencing.
This article is distributed under the terms of an Attribution–Noncommercial–Share 
Alike–No Mirror Sites license for the first six months after the publication date 
(see http://www.rupress.org/terms). After six months it is available under a Cre-
ative Commons License (Attribution–Noncommercial–Share Alike 3.0 Unported 
license, as described at http://creativecommons.org/licenses/by-nc-sa/3.0/).
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1997). BCL6 is widely believed to restrain expression of the 
plasma cell transcriptional program before the initiation of 
terminal differentiation triggered by cell surface signaling 
events (Calame et al., 2003). Its deregulation is implicated in 
the  pathogenesis  of  GC-derived  diffuse  large  B  cell  lym-
phoma (DLBCL; Kusam and Dent, 2007). Mice engineered 
to express Bcl6 constitutively in B cells developed lympho-
mas with characteristics typical of human DLBCL (Cattoretti 
et al., 2005). Furthermore, sustained expression of BCL6 in 
DLBCLs is necessary for tumor survival and proliferation 
(Polo et al., 2004; Cerchietti et al., 2009b). Therefore, un-
derstanding the molecular mechanisms in regulating BCL6 
expression has important implications in the identification of 
therapeutic targets for B cell lymphomas.
Constitutive BCL6 expression in a subset of DLBCLs occurs 
through chromosomal translocation or mutations in the pro-
moter region of BCL6 (Ci et al., 2008). However, the majority 
of DLBCLs express BCL6 in the absence of genetic lesions (Ci 
et al., 2008). Therefore, additional regulatory mechanisms must 
be used in these DLBCLs to sustain BCL6 expression. Recently, 
it has been shown that the molecular chaperone Hsp90 can be 
up-regulated to stabilize and maintain BCL6 mRNA and pro-
tein in DLBCLs (Cerchietti et al., 2009a). In addition, epigenetic 
silencing of a microRNA targeting BCL6 also indirectly con-
tributed to the maintenance of BCL6 expression in lymphomas 
(Saito et al., 2006). In this paper, we describe an unusual role for 
DNA methylation in the high level expression of BCL6 mRNA 
in lymphoma cells. Transcription of this protooncogene can be 
positively regulated by DNA methylation of intragenic CpG is-
lands. This aberrant DNA methylation, specific to lymphoma, 
acted to prevent CTCF-mediated silencing of BCL6. These re-
sults provide a graphic example of aberrant DNA methylation in 
cancer serving to promote expression of an oncogene.
RESULTS
BCL6 transcription is initiated predominately  
at the upstream transcription initiation start site
BCL6 is located at human chromosome 3q27. The locus 
contains 11 exons, including two alternative noncoding first 
exons associated with two alternative transcription initiation 
sites. Both mRNA species code for identical proteins. We 
assessed steady-state levels of BCL6 mRNA in two model 
cell lines: Raji, a Burkitt lymphoma line with a transcrip-
tional program similar to that of primary GC B cells (Epstein 
et al., 1966; Shaffer et al., 2002), and NCI-H929, a plasma cell 
myeloma cell line similar in many respects to primary plasma 
cells (Gazdar et al., 1986). By Northern analysis (Fig. S1 A) 
and by quantitative RT-PCR (not depicted), we detected 
high levels of BCL6 mRNA in Raji but were unable to de-
tect the message in H929 above background levels.
Transcript mapping using publicly available expressed 
sequence tags (Kent et al., 2002) indicated the use of two 
transcription start sites at the human BCL6 locus that differ by 
roughly 9 kb. Both transcripts code for identical proteins, differ-
ing only in the sequences found in the alternative 5 noncoding 
first exons. The biological functions of these noncoding exons, 
of the X chromosome in female mammals indicated that DNA 
methylation levels were consistently higher within transcribed 
regions on the active allele compared with the inactive allele 
(Hellman and Chess, 2007). In this case, DNA methylation may 
serve to prevent activation of functional DNA elements (such as 
cryptic promoters, recombination hotspots, or transposable ele-
ments) embedded within transcription units (Jones, 1999).
In addition to its well documented roles in impacting local 
chromatin architecture, cytosine methylation serves to alter the 
chemistry of the major groove of DNA (Bird and Wolffe, 1999). 
The presence of additional functional groups in this location can 
serve to alter the binding of transcription factors to their cognate 
recognition elements. An example of such a factor is the CCCTC-
binding factor CTCF (Lobanenkov et al., 1990), which binds 
DNA in a methylation-sensitive manner (Bell and Felsenfeld, 
2000; Hark et al., 2000; Rodriguez et al., 2010). CTCF has un-
usual properties, exerting an influence on local chromatin archi-
tecture through the formation of higher order structures (Splinter 
et al., 2006). It also has the property, when located between a 
promoter and enhancer, of blocking enhancer function (Bell 
et al., 1999), potentially through its ability to organize chromo-
somal domains within the nucleus (Yusufzai et al., 2004). There-
fore, DNA methylation has the potential to positively regulate 
gene transcription, albeit in an indirect manner, by preventing 
CTCF binding and thereby abolishing an enhancer block.
Aberrant DNA methylation has been observed in a wide   
range of cancer cells. Repetitive sequences within the inter-
genic regions of the genome, which are normally heavily meth-
ylated, often become hypomethylated in tumors (Feinberg   
et al., 1988). This global DNA hypomethylation is thought to 
contribute to genome instability during tumorigenesis (Howard 
et al., 2008). In contrast, promoter CpG islands are frequently 
hypermethylated and are strongly associated with transcrip-
tional silencing (Costello et al., 2000; Rauch et al., 2008). 
Hypermethylation has been observed at promoters of various 
types of genes that can confer a growth advantage in tumors, en-
compassing tumor suppressor genes including VHL and RB1, 
cell cycle regulators such as p15INK4b and p16INK4a, DNA repair 
factors like BRCA1 and MLH1, and cell invasion/adhesion 
proteins  such  as  E-cadherin  (Boultwood  and  Wainscoat, 
2007; McCabe et al., 2009). CpG islands outside of gene pro-
moter regions in cancer cells have also been found to be hyper-
methylated, although their functional role in regulating gene 
expression is not clear (Weber et al., 2005; Smith et al., 2007). 
Although the role of DNA methylation in gene inactivation to 
promote tumorigenesis is well documented, a role for DNA 
methylation in gene activation, particularly of oncogenes, has 
yet to be clearly demonstrated.
The BCL6 (B cell lymphoma 6) oncogene was identified 
based on its involvement in translocations, placing its expres-
sion under the control of a strong enhancer in lymphoma (Ye 
et al., 1993a,b). The gene encodes a 95-kD protein, containing 
BTB/POZ and zinc finger motifs, that functions as a tran-
scriptional repressor. In B lymphocytes, it is required for ger-
minal center (GC) formation, which is the site of antibody 
affinity maturation in secondary lymphoid tissue (Ye et al., JEM VOL. 207, August 30, 2010 
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methyltransferase  inhibitor  5-aza-2-deoxycytidine  (5-Aza-C). 
Treatment of multiple Burkitt lymphoma and DLBCL cell lines 
with this drug led to a marked alteration in steady-state levels of 
BCL6 mRNA, as assessed by quantitative RT-PCR (Fig. 2 A 
and Fig. S2 E). Inhibiting DNA methyltransferases led to three- 
to fivefold reductions in mRNA levels, which is consistent with 
a positive role for this epigenetic mark in regulation of the locus. 
if any, remain unknown. In the current system, we analyzed uti-
lization of the upstream versus downstream transcription start 
site by quantitative exon-specific RT-PCR (Fig. S1 B), finding 
that the vast majority of transcripts in Raji cells (>90%) initiate 
at the upstream start site (Fig. 1 A, locus map).
Differential DNA methylation status at BCL6 intronic  
CpG islands
Cytosine methylation is known to exert an influence on the 
transcriptional properties of DNA in mammals (Bestor, 2000; 
Jaenisch and Bird, 2003). Careful examination of the genomic 
context of human BCL6 (Fig. 1 A) revealed the presence of 
multiple CpG islands. As aberrant methylation of CpG islands 
is known to be associated with cancer (Laird, 2005; Baylin and 
Ohm, 2006), the methylation status of the CpG islands in Raji 
and H929 cell lines were determined by genomic bisulfite se-
quencing (Fig. 1 A). The most 5 CpG island (CpG island 17) 
was almost completely unmethylated in both cell lines. CpG 
island 32 and CpG island 27, in contrast, were completely 
methylated in Raji and completely unmethylated in H929. 
CpG island 38 was methylated in both cell lines, with a mar-
ginally higher level of methylation in Raji.
To gain further insights into the DNA methylation status 
across the 5 end of the BCL6 gene, we enriched for methyl-
ated DNA using the methylated CpG island recovery assay 
(MIRA; Rauch and Pfeifer, 2005; Rauch et al., 2006) in Raji 
and H929 and hybridized onto a DNA promoter tiling micro-
array. Using the MIRA-chip method, we obtained DNA 
methylation enrichment signal spanning from about 7 kb to 
+10 kb from the upstream transcription start site of BCL6, in-
cluding the entire first intronic region of the gene at 150-bp 
resolution (Fig. 1 B). Consistent with the bisulfite sequencing 
data (Fig. 1 A), a peak-finding algorithm detected differential 
enrichment of methylated CpGs at the corresponding CpG is-
lands in Raji and H929 (Fig. 1 B). In addition to robust enrich-
ment of methylated CpGs at CpG islands 32, 27, and 38 in 
Raji, DNA methylation was present in the neighboring re-
gions spreading along both ends of CpG island 32 (Fig. 1 B, 
top). H929 cells were enriched for methylated CpGs at CpG 
islands 17 and 38 but were devoid of DNA methylation in the 
entire region between these two CpG islands (Fig. 1 B, bot-
tom). Bisulfite sequencing results indicated that CpG island 17 
was only sparsely methylated in 50% of the alleles analyzed in 
H929 (Fig. 1 A). Nonetheless, this low density of methylated 
CpG in the region was detected as significant enrichment by 
MIRA-chip (Fig. 1 B, bottom), indicating a high sensitivity of 
this assay as previously reported (Rauch and Pfeifer, 2005). 
The MIRA-chip data were validated by quantitative PCR 
(Fig. S1 C), which demonstrated a strong correlation between 
the two detection methods. The hypermethylated status at the 
BCL6 intronic region in Raji cells suggested a possible role of 
DNA methylation in driving transcription of the gene.
Positive regulation of BCL6 transcription by DNA methylation
To ascertain whether DNA methylation might influence expres-
sion of BCL6 in this system, cells were treated with the DNA 
Figure 1.  Cell type–specific DNA methylation status at BCL6 intronic 
region. (A) The diagram depicts the genomic organization of the human 
BCL6 locus. Indicated are the two transcription start sites (arrows), the four 
CpG islands (17, 32, 27, and 38), and the exons (black rectangles). Below the 
cartoon, the results of genomic bisulfite sequencing are presented. Each line 
of circles indicates an individual clone sequenced in the analysis after bisul-
fite treatment and PCR. Open circles indicate CpG sites at which no DNA 
methylation is detected. Blackened circles indicate CpG sites which are 
methylated. Data shown is representative of the results of three independent 
biological replicates. (B) MIRA-chip analysis of Raji (top) and H929 (bottom) 
across the 5 end of the BCL6 locus. Each vertical line represents the mean 
normalized log2 ratio of enriched/input probe signal from two replicate sam-
ples, corresponding to the genomic location on chromosome 3 at the BCL6 
locus (UCSC genome browser HG18) as listed on the x axis. Blue and yellow 
colors represent methylated and unmethylated regions, respectively.1942 DNA methylation relieves BCL6 silencing | Lai et al.
et al., 1985). To determine whether 5-Aza-C–mediated BCL6 
down-regulation is not a result of DNA damage, Raji cells were 
treated with high (1 µM) and low (0.1 µM) nondamaging dos-
ages of 5-Aza-C. Both concentrations of 5-Aza-C resulted in 
down-regulation of BCL6 transcript and protein level after 24 h 
of treatment (Figs. S2, C and D). Phosphorylated histone 
H2AX (H2AX), a sensitive molecular marker of DNA damage 
(Rogakou et al., 1998), did not accumulate after treatment of 
Raji with either dosage of 5-Aza-C (Fig. S2 D). In contrast, Raji 
cells treated with etoposide, a topoisomerase II inhibitor which 
induces DNA damage, readily up-regulated H2AX phosphory-
lation (Fig. S2 D). Treatment of an independent cell line, the 
DLBCL cell line Su-DHL-6, with both high and low doses of 
Genomic bisulfite sequencing indicated that the transcriptional 
changes observed here were accompanied by alterations in the 
DNA methylation profiles at the intronic CpG islands (Fig. S2 A). 
Furthermore, consistent with the known role of BCL6 in speci-
fying the identity of GC B lymphocytes (Kusam and Dent, 
2007), treatment of Raji cells with 5-Aza-C led to increased 
steady-state levels of plasma cell–specific transcripts including 
PRDM1 and IRF4 (Fig. 2 B). In contrast to Raji, treatment with 
5-Aza-C in H929 did not result in changes in BCL6 expression 
or up-regulation of IRF4 and PRDM1 transcripts (Fig. S2 B).
It has been reported that genotoxic stress can lead to degra-
dation of BCL6 protein (Phan et al., 2007), and 5-Aza-C treat-
ment has been linked to induction of DNA damage (D’Incalci 
Figure 2.  Positive regulation of BCL6 transcription by DNA methylation. (A) The Raji, HsSultan, and EB1 Burkitt lymphoma cell lines were treated with  
5-Aza-C for 24 h, and BCL6 and actin mRNA abundance was determined by quantitative RT-PCR. The bar graph depicts the BCL6 to actin ratio from three 
independent replicates. Error bars indicate standard deviation. The value from untreated cells for each replicate was arbitrarily set to 1. (B) Raji cells were treated 
with 5-Aza-C for the indicated times. BCL6, IRF4, and PRDM1 mRNA abundance was determined by quantitative RT-PCR. The bar graphs depict the ratio of each 
transcript to GAPDH mRNA, with the value from untreated cells (day 0) arbitrarily set to 1. Data represent the mean of three independent replicates. Error bars indi-
cate standard deviation. (C) The diagram depicts the basic features of the BCL6 locus 5 end along with the approximate locations of primer sets used to analyze  
the chromatin immunoprecipitated with the indicated antibodies in each panel. Each ChIP primer was analyzed by quantitative PCR with the graph depicting the 
percentage of input chromatin recovered in the immunoprecipitation for each primer set. The data represent the mean of two independent biological replicates.JEM VOL. 207, August 30, 2010 
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did not decrease (Fig. S2 H), treatment of Raji with DNA 
methylation inhibitors led to dramatic reductions in the level 
and extent of all three elongation-associated modifications 
(trimethyl H3K36, dimethyl H3K79, and trimethyl H3K79), 
which is consistent with the loss of transcript (Fig. 2 C, bot-
tom). These results strongly indicate that the presence of DNA 
methylation directly promotes the transcription of the BCL6 
gene in lymphoma cell lines.
Presence of DNase I hypersensitive sites within CpG islands 
32 and 27 in the absence of DNA methylation
One of the proposed regulatory mechanisms ascribed to DNA 
methylation is to prevent the binding of transcription factors 
(Bird and Wolffe, 1999). DNase I hypersensitive site analysis 
was used to identify putative transcription factor binding sites 
within the human BCL6 locus in Raji and H929. We observed 
a complicated pattern of nuclease hypersensitivity at the locus 
that differed with cell type (Fig. 3). At the extreme 5 end of the 
locus, we observed a hypersensitive site located 2 kb upstream 
of the transcription start site that was present in both Raji and 
H929 (site C1; Fig. 3 A, and B). We also identified a second 
constitutive hypersensitive site (site C2; Fig. 3, A and B) which 
mapped to the region between CpG islands 32 and 27 in the 
first intron. A series of additional hypersensitive sites at the 5 
end of the locus differed in intensity between the two cell types. 
Two sites (sites B1 and B2; Fig. 3, A and B) were present in 
both cell types but were more pronounced in Raji. Two other 
5-Aza-C resulted in reduction of BCL6 transcript level but only 
after 3 d of incubation in the presence of the drug (Fig. S2 E). 
We determined that this delayed BCL6 down-regulation was 
the result of a slower growth rate in Su-DHL-6 cells compared 
with Raji (Fig. S2 F). Collectively, these results indicate that the 
observed down-regulation of BCL6 was a consequence of DNA 
methyltransferase inhibition that is dependent on active cell divi-
sion and not a consequence of DNA damage.
To further investigate whether the intronic DNA methyl-
ation directly regulates BCL6 transcription, we first examined 
several  histone  modifications  that  correlate  with  promoter 
chromatin accessibility or active transcription status across the 
BCL6 gene locus by chromatin immunoprecipitation (ChIP). 
PCR amplicons were designed to tile the human BCL6 locus 
at 500-bp intervals beginning upstream of the 5 transcrip-
tion start site and extending 3 of the alternate transcription 
start site, spanning a genomic region of 15 kb (Fig. 2 C). First, 
the methylation status of histone H3 lysine (K) 4 and the acet-
ylation status of histone H3 were analyzed across the 5 end of 
the locus. The presence of both histone modifications at gene 
promoters is associated with genes either actively being tran-
scribed or with the potential to be transcribed (Barski et al., 
2007; Birney et al., 2007). Enrichment of both marks was ob-
served just downstream of the transcription start site at the ac-
tive locus in Raji (Fig. 2 C, top left and center), whereas the 
total histone H3 level remained constant throughout the 5 
end of the transcription unit (Fig. S2 G). At the inactive locus 
in H929, peaks for both marks were also observed near the 
transcription start site but at a lesser magnitude (Fig. 2 C, top 
left and center). In addition, a second peak of trimethyl H3K4 
was observed in a region coincident with the differentially 
methylated CpG islands CpG 32 and CpG 27 (Fig. 2 C, top 
left) only in H929. These patterns of histone modification at 
the BCL6 locus are very consistent with the patterns observed 
in the human genome (Birney et al., 2007; Guenther et al., 
2007; Heintzman et al., 2007)—notably, the presence of a 
sharp peak of active chromatin marks just downstream of the 
transcription start site of an actively transcribed gene.
The presence of the same marks—trimethyl H3K4 and 
acetyl H3—at the inactive locus in H929 suggests that the core 
promoter may be poised to fire in plasma cells despite the lack 
of detectable transcripts. However, despite the active chroma-
tin conformation at the promoter of BCL6 in plasma cells, we 
did not observe enrichment of RNA polymerase II (Fig. 2 C, 
top right) or histone modifications that correlate with active 
transcription, such as trimethyl H3K36, dimethyl H3K79, and 
trimethyl H3K79 (Fig. 2 C, bottom), at the promoter or along 
the BCL6 gene in H929. In contrast, enrichment of these 
marks was readily detected throughout the transcription unit of 
BCL6 in Raji (Fig. 2 C, bottom). These results are consistent 
with the transcription status of BCL6 in the two cell types.
To further confirm a role of DNA methylation in directly 
regulating transcription of BCL6, we treated Raji with DNA 
methylation inhibitor 5-Aza-C for 72 h and assessed altera-
tions in the histone modifications that correlate with tran-
scriptional elongation. Although the level of trimethyl H3K4 
Figure 3.  Presence of DNase I hypersensitive sites within CpG islands 
32 and 27 in the absence of DNA methylation. (A) The diagram depicts 
the approximate location of the genomic features of the BCL6 locus along 
with the restriction fragments and probes used for indirect end labeling. The 
approximate locations of the observed hypersensitive sites are indicated on 
the diagram. (B) The 5 end of the BCL6 locus was analyzed by DNase I diges-
tion using the reference restriction enzyme XbaI. Wedges indicate concentra-
tions of DNase I. The locations of restriction sites and the probe used for the 
Southern blot are depicted in A. Arrows indicate the major DNase I hyper-
sensitive sites and their locations are summarized in A. Marker positions were 
measured from ethidium-stained gel before transfer. Data shown is represen-
tative of results from at least three independent experiments.1944 DNA methylation relieves BCL6 silencing | Lai et al.
intronic sites coinciding with the differentially methylated CpG 
islands, were sites of enrichment in these datasets. Importantly, 
cell types used for these analyses did not express BCL6. In addi-
tion, the occupancy of these sites by CTCF was determined ex-
perimentally by ChIP in our system (Fig. 4, A and B). In both 
Raji and H929, modest peaks of CTCF enrichment were ob-
served at genomic regions coincident with the constitutive hy-
persensitive sites (sites C1 [primer set C] and C5/C6 [primer sets 
EE and FF]) flanking the locus. In H929, but not in Raji, we ob-
served robust enrichment for CTCF across a region of intron 1 
coinciding with the putative CTCF binding sites and with the 
differentially methylated CpG islands. Enrichment was highest 
at primer sets L and M which correspond roughly to predicted 
CTCF intronic sites (sites 3–6; Fig. 4, A and B). Another peak of   
substantial enrichment in the first intron (primer set O) correlated 
with an additional putative CTCF site (site 7; Fig. 4, A and B). 
As a test of our model of DNA methylation-regulated binding 
of CTCF at BCL6, we examined CTCF occupancy of these 
same sites in Raji cells treated with 5-Aza-C. We observed ele-
vated  CTCF  occupancy  at  intronic  sites  3–6  after  5-Aza-C 
treatment (Fig. 4 B), further demonstrating that DNA methyla-
tion serves as a regulator of CTCF binding at these sites.
The functional relevance to BCL6 expression of CTCF 
binding within the intronic region was probed by manipulation 
of CTCF expression levels. Lentiviral particles were prepared to 
deliver a short hairpin RNA designed to target CTCF and in-
troduced into H929. After infection, cells were selected briefly 
for integration and live cells were purified for transcript analysis. 
RNA analysis indicated that depletion of CTCF transcript levels 
was accompanied by a corresponding increase in levels of BCL6 
mRNA (Fig. 4 C). CTCF protein depletion in the presence of 
short hairpin (sh) RNA was also confirmed (Fig. S4 A). The 
level of BCL6 mRNA detected in H929 in the absence of 
CTCF is comparable to the level of BCL6 mRNA in B cell lines 
(Fig. 2, A and B), strongly implying that CTCF plays an active 
role in control of BCL6 expression. As BCL6 encodes a master 
regulator of the transcriptional program, we analyzed additional 
transcripts to ascertain whether CTCF depletion elicited altera-
tions consistent with the action of BCL6. Transcript levels diag-
nostic (within the cell lines used) for GC identity including 
MTA3 and AID were elevated (Fig. 4 C). In contrast, transcript 
levels for multiple markers of the plasma cell transcriptional pro-
gram, including IRF4, PRDM1, and XBP1, decreased after de-
pletion of CTCF. These data are consistent with CTCF playing 
a key regulatory role at the BCL6 locus and, by extension, in the 
elaboration of cell type–specific transcription during the B cell to 
plasma cell transition.
Elevated DNA methylation at BCL6 intronic CTCF binding 
site in primary lymphoma cells
Next, we asked whether changes in intronic BCL6 DNA 
methylation status also occur in a similar fashion during the tran-
sition from GC B cell to plasma cell in an immune response. 
We performed genomic bisulfite sequencing analysis on 
BCL6 intronic CpG islands in primary human GC B cells and 
plasma cells isolated from tonsil. Little DNA methylation was 
sites (sites P1 and P2; Fig. 3, A and B), coinciding with CpG   
islands 32 and 27, respectively, were apparent only in H929. 
Because sites P1 and P2 are not present in Raji where DNA 
methylation is detected, these sites could represent the presence 
of methylation-sensitive DNA binding factors.
The remainder of the coding sequence was also analyzed. No 
hypersensitivity was observed in genomic DNA corresponding 
to a HindIII fragment covering the 3 end of intron 1 through 
intron 4 (unpublished data). In contrast, the HindIII fragment 
covering a region from intron 4 to the 3 UTR (Fig. S3, top) ex-
hibited two diffuse hypersensitive regions that mapped toward 
the 3 end of the transcription unit (sites C3 and C4; Fig. S3 A). 
DNase I analysis of the far 3 end of the locus was also performed 
(Fig. S3, top). Two constitutive hypersensitive sites were ob-
served (sites C5 and C6; Fig. S3 B). Thus, the human BCL6  
locus  presents  a  complex  pattern  of  nuclease  hypersensitivity 
marked by constitutive sites flanking the locus, cell type-specific 
sites within the 5 end of the transcription unit, and additional 
constitutive sites within the 3 end of the transcription unit.
CTCF binding at BCL6 negatively regulates its transcription
The presence of DNA methylation-sensitive DNase I hypersen-
sitivity within the first intron of BCL6 was somewhat reminis-
cent of the situation at the mammalian H19/IGF2 locus, where 
CTCF is present to block enhancer activity at this imprinted   
locus (Bell and Felsenfeld, 2000; Hark et al., 2000). The pres-
ence of putative binding sites for CTCF at BCL6 was therefore 
analyzed in silico. ChIP data from a whole-genome analysis of 
CTCF binding (Kim et al., 2007) was used to identify putative 
CTCF sites in those loci. Using a motif discovery tool (Li, 2009), 
11,000 CTCF binding sites (Fig. S4 B, motif logo) were iden-
tified in the 13721 ChIP-chip CTCF loci, from which a motif 
model (position weight matrix) was generated (Fig. S4 B). The 
model was subsequently used to scan for putative CTCF binding 
sites in the genomic DNA at BCL6. High score sites that are also 
conserved across a series of mammalian species are reported as 
putative CTCF binding sites. Two putative binding sites were 
observed at a region coincident with the 5 constitutive hyper-
sensitive site C1 (Fig. 4 A and Fig. S4 C). An additional predicted 
CTCF site colocalized with the 3 constitutive hypersensitive 
sites C5/C6 (Fig. 4 A and Fig. S4 D). Multiple putative CTCF 
elements were found within intron 1. Most putative CTCF 
binding sites within the first intron of human BCL6 contain at 
least one CpG dinucleotide, presenting the opportunity for DNA 
methylation to modulate the interaction of CTCF with these re-
gions of the genome (Fig. 4 A and Fig. S5). In general, sequence 
conservation across mammals is higher at the putative CTCF sites 
flanking the locus than at the individual intronic elements, im-
plying a strict evolutionary requirement for maintenance of DNA 
sequence at those sites (Fig. S4, C and D; and Fig. S5).
Whether these putative sites were bound by CTCF was 
verified in two independent ways. First, these regions were ana-
lyzed in two publicly available datasets of CTCF localization in 
the human genome (Barski et al., 2007; Kim et al., 2007) assem-
bled using different analysis techniques. In all cases, the putative 
CTCF binding sites identified in our analysis, including the   JEM VOL. 207, August 30, 2010 
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DNA methylation status at intronic CTCF sites within the 
BCL6 locus in a panel of B cell lymphoma (DLBCL) and 
plasma cell myeloma samples, which express high and low 
levels of BCL6, respectively (Table S2, clinical data for lym-
phoma samples). The BCL6 transcript level in the two cancer 
cell types was determined by quantitative RT-PCR (Fig. 5 A).   
The expression level of BCL6 in lymphoma samples was 
lower than that of Raji (Fig. 5 A), likely as a result of the het-
erogeneity of lymphoma samples (comprising both tumor 
and normal cell types). Despite this heterogeneity, we still 
detected significantly higher levels of BCL6 transcripts in 
detected at the intronic CpG islands in these cells (Fig. S6 A), 
indicating that the DNA methylation events described in this 
paper are likely to be either cancer or cell line associated.
Accordingly,  we  investigated  whether  hypermethyl-
ation in BCL6 intronic region also occurs in primary lym-
phoma cells or if it is a cell line–specific phenomenon. Down- 
regulation of BCL6 expression can promote cell cycle arrest 
(Phan et al., 2005) and can reactivate the tumor suppressor gene 
p53 (Phan and Dalla-Favera, 2004); therefore, it is likely that 
lymphomas adapt regulatory mechanisms to ensure high ex-
pression of BCL6. To address this question, we compared the 
Figure 4.  CTCF binding controls BCL6 expression. (A) The diagram depicts the genomic features of the BCL6 locus, including the locations of hypersensitive 
sites and the PCR amplicons used in the ChIP analysis. (B) The graph (left) depicts a representative example of CTCF ChIP at the BCL6 locus in Raji and H929. CTCF 
enrichment at intronic CTCF sites was also analyzed in Raji after 5-Aza-C treatment for 5 d (right). The graph represents mean enrichment levels from two ex-
periments for each treatment condition. Data are presented as the percentage of input for each primer set, determined by quantitative PCR with comparison  
of immunoprecipitated DNA with a standard curve of DNA purified from input chromatin for each sample. (C) mRNA abundance in H929 cells treated with CTCF 
shRNA or empty vector was determined by quantitative RT-PCR. Data represent the mean of three independent replicates. Error bars indicate standard deviation.1946 DNA methylation relieves BCL6 silencing | Lai et al.
in part, through CTCF exclusion in a DNA methylation-
  independent mechanism mediated through extracellular signal-
ing events (Lefevre et al., 2008). The gain of DNA methylation 
in B cell lymphomas may result from selective pressure to sta-
bly maintain BCL6 expression outside the GC microenviron-
ment in the absence of the necessary extracellular stimuli.
We have observed differential binding of CTCF to con-
served sites located in close proximity to, or contained within, 
the differentially methylated regions of intron 1. Binding of 
CTCF to these sites in plasma cells, but not in B cells, could 
lead to blockade of an enhancer element (Fig. S7 A), precisely 
as occurs at the imprinted H19/IGF2 locus (Bell and Felsenfeld, 
2000; Hark et al., 2000). Alternatively, the presence of CTCF 
in the intronic BCL6 region can directly block transcription of 
the gene (Fig. S7 B) as previously described (Lobanenkov   
et al., 1990; Filippova et al., 1996). To our knowledge, this is 
the first example of differentially methylated CTCF binding 
sites located within the transcription unit they are proposed   
to regulate. This model of CTCF-regulated transcription is 
bolstered by depletion of CTCF by RNA interference in 
plasma cell lines, which leads to increased expression of BCL6 
(Fig. 4 C) and alterations to the cellular transcriptional pro-
gram consistent with a change in cell identity (Fig. 4 C).
Although this model explains the differential binding of 
CTCF to the BCL6 locus in these two cell types, it does not 
address the reason why BCL6 is regulated by such a complicated 
mechanism. The biology of genomic imprinting is embedded 
within evolutionary selective pressures that are not entirely   
understood (Tilghman, 1999; Reik and Lewis, 2005). That 
genes subject to complex patterns of expression, like imprinted 
genes, should have correspondingly complicated regulatory   
lymphomas compared with myelomas (as determined by a 
one-tailed Student’s t test where P = 0.05; Fig. 5 A).
Methylation-specific PCR (MSP) was used to detect DNA 
methylation in the same tumor samples. We tested for the meth-
ylation status of CpGs at intronic CTCF sites 3, 4, and 5, where 
CTCF occupancy is highest by ChIP in H929 plasma cells 
(Fig. 4). Although a gain of CpG methylation signal at intronic 
site 5 was not detected (not depicted), we observed significantly 
higher signals of DNA methylation along the tandem CTCF 
sites 3 and 4 in lymphomas compared with the myelomas (as de-
termined by a one-tailed Student’s t test where P = 5.53 × 106; 
Fig. 5 B). Differential methylation status at the CpG dinucleo-
tides at CTCF sites 3 and 4 was also observed in Raji and H929 
cells (Fig. S6 B and Fig. 1 B). Of the 11 lymphoma samples ana-
lyzed, only one sample had detectable level of translocation at 
the BCL6 locus (Fig. S6 C). This lymphoma sample had one of 
the lowest methylation signals at CTCF sites 3 and 4 (Fig. S6 D). 
This result supports the hypothesis that elevated DNA methyla-
tion is a mechanism that contributes to sustained high level tran-
scription of BCL6 selectively in lymphomas that do not have 
translocation at the BCL6 locus. Altogether, the results from this 
paper demonstrate an intriguing new role for DNA methylation 
in transcriptional activation of an oncogene in cancer.
DISCUSSION
The role of DNA methylation in regulating gene expression has 
been extensively studied in the context of cancer, where aber-
rant accumulation of this epigenetic mark is strongly associated 
with transcriptional silencing of tumor suppressors (Feinberg 
et al., 2002; Jones, 2003; Baylin and Ohm, 2006). The data 
presented in this work provide evidence that aberrant DNA 
methylation in the context of cancer cells can also promote ex-
pression of an oncogene, BCL6. Presumably, the DNA meth-
ylation events described here serve to stabilize a functional 
chromatin state at the locus that excludes CTCF binding to in-
tronic regulatory DNA and confers a growth advantage.
The regulatory mechanisms controlling transcription at   
the BCL6 locus are partially understood. BCL6 mRNA is   
expressed at high levels in GC B cells (Cattoretti et al., 1995; 
Onizuka et al., 1995) and its transcript levels are negatively 
controlled via autoregulatory elements in exon 1 and the first 
intron of the locus, sites of frequent mutation in lymphoma 
(Wang et al., 2002). IRF4 directly represses BCL6 expression 
during the transition from GC B cell to plasma cell, and by 
binding to regulatory DNA at the 5 end of the transcription 
unit in a region that serves as a target for mutation in cancer 
(Saito et al., 2007). In this paper, we showed that gain of DNA 
methylation events at CTCF sites in the first intron of BCL6 
are restricted to lymphomas and do not occur during normal   
B cell differentiation in the GC reaction (Fig. S6 A) when BCL6 
expression is developmentally up-regulated. Our results sug-
gest that DNA methylation acts in a cancer-specific manner   
to block access of CTCF to critical cis-acting regulatory DNA 
at BCL6 in a manner analogous to mutation of the BCL6   
or IRF4 binding sites. It is likely that during a normal GC reac-
tion, BCL6 transcription is activated in B lymphocytes, at least 
Figure 5.  DNA methylation analysis at CTCF binding sites in BCL6 
intronic region of primary tumors. (A) Quantitative RT-PCR analysis of BCL6 
mRNA abundance in lymphoma and plasma cell myeloma samples. The box-
and-whisker plot illustrates the BCL6 expression level of 11 lymphoma and 8 
myeloma samples as the percentage of expression level in Raji (y axis is plot-
ted in log scale). The horizontal bar within the box represents the median 
(50th percentile) of the data points within each sample group, whereas the 
top and the bottom of the box represent the upper and lower quartile range 
(75th and 25th percentile), respectively. The whiskers represent the spread of 
data points within 1.5 interquartile range, and outliers are represented as open 
circles. (B) MSP analysis of CpGs at CTCF sites 3 and 4 in BCL6 intronic region. 
Intensities of 32P signal in the Southern blot of MSP and the corresponding 
unmethylated-specific PCR (USP) were quantified and represented as MSP/
USP intensity ratio. MSP/USP primer locations and the CpGs being analyzed 
are shown in Fig. S6 B. The box-and-whisker plot compares the MSP/USP 
intensity ratio of the same lymphoma and myeloma samples analyzed in A.JEM VOL. 207, August 30, 2010 
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fragments were enriched from 200 ng of sonicated DNA using the MethylCol-
lector Ultra kit (Active Motif) according to the manufacturer’s protocol. Input 
and methylated CpG DNA fragments were amplified (WGA2; Sigma-Aldrich), 
labeled with Cy3 and Cy5 random monomers (TriLink Biotechnologies), re-
spectively, and hybridized onto a NimbleGen 2.1M Deluxe Human Promoter 
Array (Roche). Probe labeling, microarray hybridization, and processing were 
performed according to NimbleGen’s protocol. The microarray slides were 
scanned using a DNA microarray scanner (G2565BA; Agilent Technologies). 
Images were processed using the NimbleScan software. All microarray data files 
were deposited into GEO under accession no. GSE22884.
Data normalization. A two-step normalization approach was used, where 
the first step is designed to correct for GC bias and dye bias within a chip (in-
trachip correction) and the second step corrects for variations across chips (in-
terchip correction). The first step was within-chip normalization. First, all 
probes were binned according to their GC content. The GC content was com-
puted as a ratio of C and G nucleotides to the total number of nucleotides in the 
probe sequence. The overall variability in GC content values was used to com-
pute bin width according to zero-stage rule described in Wand (1997). These 
bin widths are proven to be approximate L2 optimal; i.e., they minimize mean 
integrated square error. The bins with fewer probes were then merged so that 
each bin contains at least 500 probes. Within each bin, Lowess regression 
(Cleveland et al., 1988; Hastie and Tibshirani, 1990) was used to predict log-
transformed cy5 values as a smooth function of log-transformed cy3 values. The 
scaled (median of absolute residuals is used for scaling) difference between ob-
served and predicted log(cy5) values were used as normalized signal.
The second step was between-chip normalization. Once the data were 
corrected for dye and GC bias as described in the first step, quantile normal-
ization was used to correct for between sample variations. The resulting data-
set was referred to as normalized data and was used for further investigations.
Identification of methylation sites across the genome. A variant of the 
ACME algorithm (Scacheri et al., 2006) was used to identify peak regions. 
This algorithm depends on three user-specified tuning parameters: window 
size (w), signal threshold (s), and p-value threshold (p). Any probes in the 
data that are above threshold (s) are considered positive probes.
Enrichment p-value is computed using hyper geometric distribution   
by looking at observed number of positive probes (probes with signal > s) 
within a sliding window of size w centered on each probe as follows:
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where N denotes total number of probes, K denotes total number of 
probes with signal > s (signal threshold defaults to 10th percentile), n denotes 
number of probes inside the sliding window of size w (defaults to 500), and 
x denotes number of probes inside the sliding window with signal > s.
Next, the binding sites are identified as runs of positive enrichment   
p-values, i.e., below threshold (default is p(x) < p). Each positive run of this 
sequence is considered to be a binding site. We do not correct the enrichment 
p-values for multiple comparisons, as they are only used as a means of finding 
regions of interest in the genome rather than a strict statistical significance 
level. The MIRA-chip data described in this paper have been deposited at 
the GEO database (GSE22884).
5-Aza-C and etoposide treatment
Cells were suspended at a density of 0.2 × 106 cell/ml and grown in normal 
culture media for 24 h. Cells were treated by addition of 0.1 or 1 µM 5-Sza-C 
(Sigma-Aldrich) for 24–72 h. For etoposide treatment in Raji, cells were 
treated with either 5 µM etoposide (Sigma-Aldrich) or equal volume of 
DMSO as vehicle control for 24 h. To analyze Bcl6 and phosphorylated 
H2A.X protein level, cells were harvested and lysed in 1 M Tris, pH 6.8, 
with 8 M urea and 1% SDS for SDS-PAGE. Western blotting was per-
formed using anti-Bcl6 (Santa Cruz Biotechnology, Inc.; sc-858), anti–-
H2AX (Millipore; 05–636), and anti-actin (Millipore; MAB1501).
mechanisms is, perhaps, not surprising. BCL6, in contrast, pres-
ents an expression pattern reminiscent of many developmentally 
regulated genes. Transcription from the locus is maintained in a 
repressed state through much of development. There is a burst 
of activity in the developmental stage corresponding to the GC 
reaction, and then the gene is silenced concomitant with termi-
nal differentiation to a plasma cell (Kusam and Dent, 2007). This 
pattern, OFF-ON-OFF, is recapitulated at many genes in mul-
ticellular organisms. However, two aspects of BCL6 biology 
suggest unique requirements for maintenance of a repressed state 
in most cell types. First, BCL6 functions as an oncogenic tran-
scription factor (Melnick, 2005; Staudt and Dave, 2005). Sec-
ond, high level expression of BCL6 leads to down-regulation of 
a set of genes integral to maintenance of genome integrity (Phan 
and Dalla-Favera, 2004; Ranuncolo et al., 2007). Sustained ex-
pression is sufficient to trigger lymphomagenesis, and experi-
mental  models  have  elegantly  demonstrated  this  very  point 
(Cattoretti et al., 2005). That the primary promoter used in B 
lymphocytes should be insulated by the action of CTCF in cells 
not participating in the GC reaction may be reflective of the in-
herent danger of expressing BCL6 protein at high levels.
The data presented in this work are consistent with a surpris-
ing role for DNA methylation in transcriptional regulation of an 
oncogene in cancer. Mechanistic predictions derived from these 
results suggest that, contrary to predominant models, DNA meth-
ylation likely contributes to transcriptional regulation in more 
than one capacity. The fundamental outcome of DNA methyl-
transferase activity is to alter the chemical properties and informa-
tion content of the DNA major groove. We predict that evolution 
has used this information content to regulate multiple aspects of 
chromosomal biology, including transcriptional activation.
MATERIALS AND METHODS
Cell lines
All cell lines used in this work were obtained from American Type Culture 
Collection and were maintained in RPMI 1640 medium (Invitrogen) with 
10% FBS.
Nucleic acid extraction and manipulation
Total RNA was isolated using TRIzol reagent (Invitrogen) according to the 
manufacturer’s protocol. Genomic DNA was extracted as previously described 
(Laird et al., 1991). cDNA was synthesized as previously described (Fujita et al., 
2004). For genomic bisulfite sequencing, extracted DNA was treated with so-
dium bisulfite as previously described (Frommer et al., 1992). Primers used for 
RT-PCR and amplification of bisulfite converted DNA are listed in Table S1.
RNA analysis
For Northern analysis, total RNA was electrophoresed in agarose gels, trans-
ferred to Hybond-N+ membrane (GE Healthcare) and hybridized using 
ExpressHyb hybridization solution (Takara Bio Inc.) according to the man-
ufacturer’s protocol. The probe was labeled with -[32P]dCTP using Prime-It 
RmT Random Primer Labeling kit (Agilent Technologies). The radiola-
beled signals were detected using phosphor screen (GE Healthcare) and 
phosphor imager Storm 860 (Molecular Dynamics). Template DNA for ran-
dom priming was prepared from a BCL6 cDNA clone (Fujita et al., 2004). 
The primers used are listed in Table S1.
MIRA-chip analysis
Genomic DNA purified from Raji and H929 were sonicated using a Bioruptor 
(Diagenode) to generate 200–500-bp fragments. Methylated CpG DNA   1948 DNA methylation relieves BCL6 silencing | Lai et al.
Primers used for MSP/USP analyses are listed in Table S1. Analysis of BCL6   
translocation  status  was  performed  according  to  the  method  described   
by Lossos et al. (2003).
Isolation of tonsillar B cells
Fresh human tonsil was obtained from the Emory University Pathology ser-
vice. Appropriate institutional (IRB) approvals were obtained. Primary GC 
B cells and plasma cells were purified as previously described (Cattoretti   
et al., 2006) with modifications. Tonsil specimens were processed into single 
cell suspension in PBS, followed by mononuclear cell isolation using a   
Ficoll-Hypaque gradient. Tonsillar mononuclear cells were washed twice with 
PBS and resuspended in PBS with 2% FBS and 0.02% NaN3. T cells were 
depleted by incubating sample with purified mouse anti–human CD4 (clone 
OKT4; eBioscience) and anti-CD8 (clone OKT8; eBioscience) antibodies, 
followed by sheep anti–mouse IgG Dynal beads (Invitrogen). CD4+ and 
CD8+ T cells were then removed by magnetic separation. T cell–depleted 
tonsillar mononuclear cells were subsequently stained with the following 
monoclonal antibodies for FACS purification: PE-IgD (BD), PECy7-CD38 
(clone HIT2; eBioscience), and Pacific blue–CD20 (clone 2H7; eBiosci-
ence). Cell sortings were performed using a FACSVantage (BD) with Digital 
Option. GC B cells were defined as CD20+CD38+IgD cells, and plasma 
cells were defined as CD20loCD38hiIgD cells.
Online supplemental material
Fig. S1 shows BCL6 mRNA transcript analysis in cell lines and validation 
of MIRA-chip data by PCR. Fig. S2 shows effects of 5-Aza-C treatment in 
BCL6 expressions in cell lines. Fig. S3 shows additional DNase I hypersen-
sitivity sites identified at 3 end of BCL6. Fig. S4 shows depletion of CTCF 
protein in shCTCF transfected cells and predicted CTCF binding sites within 
BCL6 locus. Fig. S5 shows intronic CTCF binding sites at BCL6. Fig. S6 
shows DNA methylation analysis at CTCF binding sites and BCL6 trans-
location status in primary lymphoma cells. Fig. S7 shows a possible mecha-
nism of CTCF-mediated transcriptional silencing of BCL6. Table S1 shows 
primer sequences used for all experiments. Table S2 shows clinical data for 
primary lymphoma samples used in this study. Online supplemental material 
is available at http://www.jem.org/cgi/content/full/jem.20100204/DC1.
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